Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

For the first quarter of this year, J&J’s total sales of $21.9 billion were up 4.2% over the start of 2024, when accounting ...

Shares of Johnson & Johnson and Amgen are trading lower Wednesday morning, sending the Dow Jones Industrial Average into negative territory. Supported by world-class markets data from Dow Jones ...

Johnson & Johnson is set to release first-quarter results on Tuesday before the market opens. Here is what you need to know.

Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.

The iconic Dow Jones Industrial Average lost 10.1% ... What's really helped Johnson & Johnson deliver rock-solid operating results is its emphasis on pharmaceuticals. Despite novel drugs ...